D Orazio & Associates Inc. Has $694,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

D Orazio & Associates Inc. boosted its stake in Abbott Laboratories (NYSE:ABT) by 5.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,233 shares of the healthcare product maker’s stock after purchasing an additional 251 shares during the quarter. D Orazio & Associates Inc.’s holdings in Abbott Laboratories were worth $694,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Three Seasons Wealth LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $1,428,000. Kelly Financial Services LLC acquired a new position in Abbott Laboratories during the first quarter valued at approximately $216,000. Voleon Capital Management LP acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $273,000. Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Abbott Laboratories by 5.5% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,095,443 shares of the healthcare product maker’s stock valued at $133,691,000 after buying an additional 57,499 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG lifted its holdings in Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after purchasing an additional 2,774 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director now owns 34,058 shares in the company, valued at $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $135.41 on Friday. The stock has a fifty day simple moving average of $131.50 and a two-hundred day simple moving average of $126.42. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The firm has a market cap of $235.59 billion, a price-to-earnings ratio of 17.70, a price-to-earnings-growth ratio of 2.52 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.74%. Abbott Laboratories’s dividend payout ratio is 30.61%.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent research reports. Morgan Stanley raised their price objective on Abbott Laboratories from $117.00 to $127.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 17th. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price target (up previously from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Royal Bank of Canada upped their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Thursday, April 17th. Bank of America increased their price target on Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Wells Fargo & Company increased their price objective on Abbott Laboratories from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, April 17th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $142.59.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.